Efficacy and Safety of Rivaroxaban Versus Enoxaparin in Prevention of Recurrence of Venous Thrombo-Embolism Events in Cancer Patients: A Meta-Analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Rivaroxaban is a viable alternative to enoxaparin for managing venous thromboembolism (VTE) in cancer patients, showing similar safety and efficacy without significant drawbacks.
Area Of Science
- Oncology
- Hematology
- Pharmacology
Background
- Venous thromboembolism (VTE) is a common complication in cancer patients.
- Enoxaparin is a standard treatment, but alternatives are sought.
Purpose Of The Study
- To compare the effectiveness and safety of rivaroxaban versus enoxaparin in cancer patients with VTE.
- To evaluate outcomes including VTE recurrence, major bleeding, and mortality.
Main Methods
- Systematic literature search of PubMed, Scopus, and Google Scholar up to April 2023.
- Inclusion of studies comparing rivaroxaban and enoxaparin in cancer patients with VTE.
- Meta-analysis of VTE occurrence, major bleeding, and mortality using Review Manager 5.2.
Main Results
- Analysis included 8 articles and 2276 patients.
- Rivaroxaban showed statistically insignificant reductions in VTE occurrence (RR: 0.83) and major bleeding (RR: 0.79).
- Mortality reduction with rivaroxaban was also statistically insignificant (RR: 0.74).
Conclusions
- Rivaroxaban is a potential alternative to enoxaparin for VTE management in malignancy.
- No significant drawbacks were observed with rivaroxaban compared to enoxaparin.
- Further research may solidify rivaroxaban's role in this patient population.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...